Literature DB >> 19223543

Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells.

Marleen M van Loenen1, Renate S Hagedoorn, Michel G D Kester, Manja Hoogeboom, Roel Willemze, J H Frederik Falkenburg, Mirjam H M Heemskerk.   

Abstract

Adoptive transfer of antigen-specific T cells is an attractive strategy for the treatment of hematologic malignancies. It has been shown that T cells recognizing minor histocompatibility antigens (mHag) selectively expressed on hematopoietic cells mediate antileukemic reactivity after allogeneic stem cell transplantation. However, large numbers of T cells with defined specificity are difficult to attain. An attractive strategy to obtain large numbers of leukemia-reactive T cells is retroviral transfer of mHag-specific T-cell receptors (TCR). TCR transfer into T cells specific for persistent viruses may enable these T cells to proliferate both after encountering with viral antigens as well as mHags, increasing the possibility of in vivo survival. We analyzed whether the dual specificity of the TCR-transferred T cells after repetitive stimulation via either the introduced antileukemic HA-2-TCR or the endogenous cytomegalovirus (CMV) specific CMV-TCR was preserved. We show that after repetitive stimulation, T cells skew to a population predominantly expressing the triggered TCR. However, HA-2-TCR-transferred CMV-specific T cells with high antileukemic HA-2-TCR expression but low CMV-TCR expression were able to persist and proliferate after repetitive stimulation with pp65. Moreover, HA-2-TCR-transferred CMV-specific T cells remained dual specific after repetitive stimulation and TCR expression could be reverted after additional stimulation via the previously nonstimulated TCR, restoring high-avidity interactions. These data imply persistence of TCR-transferred virus-specific T cells with both antileukemic and antivirus reactivity in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223543     DOI: 10.1158/0008-5472.CAN-08-2523

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies.

Authors:  Marleen M van Loenen; Renate de Boer; Renate S Hagedoorn; Esther H M van Egmond; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 3.  Adoptive T cell therapy of cancer.

Authors:  Malcolm K Brenner; Helen E Heslop
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

4.  T-cell receptor gene transfer for the treatment of leukemia and other tumors.

Authors:  Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

5.  A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells.

Authors:  Marleen M van Loenen; Renate de Boer; Ellis van Liempt; Pauline Meij; Inge Jedema; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

6.  Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation.

Authors:  Steven Lawrence Rosinski; Brad Stone; Scott S Graves; Deborah H Fuller; Stephen C De Rosa; Gregory A Spies; Gregory J Mize; James T Fuller; Rainer Storb
Journal:  Transplantation       Date:  2015-10       Impact factor: 4.939

Review 7.  Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.

Authors:  L A Marr; D E Gilham; J D M Campbell; A R Fraser
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 8.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

9.  PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

Authors:  Wolfgang Koestner; Martin Hapke; Jessica Herbst; Christoph Klein; Karl Welte; Joerg Fruehauf; Andrew Flatley; Dario A Vignali; Matthias Hardtke-Wolenski; Elmar Jaeckel; Bruce R Blazar; Martin G Sauer
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

10.  Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells.

Authors:  Marleen M van Loenen; Renate S Hagedoorn; Renate de Boer; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.